Current State-of-Art of Extracellular Vesicles for Targeting Gene Therapy in Neurological Disorders

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 3512

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Interests: non-viral vectors; gene delivery; neurological diseases; extracellular vesicles; translational research

E-Mail Website
Guest Editor
Department of Anatomy, Rostock University Medical Center, 18055 Rostock, Germany
Interests: neurobiology; neuroscience; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Extracellular vesicles (EVs) are achieving considerable accomplishments in targeted gene therapy, opening a new frontier to develop gene delivery strategies for neurological disorders. In addition to the cargo of different proteins, lipids, and nucleic acid, EVs isolated from patients diagnosed with Alzheimer’s and Parkinson’s disease and recently also multiple sclerosis show an altered genetic cargo in the form of miRNA. This has boosted the EVs’ role as biomarkers in the diagnosis of human neurological diseases. However, so far, most EVs studies have been performed using in vitro and in vivo models. Standardization of methodologies and testing across human neurodisorders still represent key challenges. This Special Issue aims to harvest the latest advanced studies of EVs in diagnosing and treating central nervous system diseases, sharing knowledge and data with readers and scientists working in this discipline to foster an effective and safe clinical translation of these unique intercellular delivery vehicles.

Dr. Nicola Orefice
Prof. Markus Kipp
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-viral vectors
  • gene delivery
  • neurological diseases
  • extracellular vesicles
  • translational research

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1235 KiB  
Review
Chemically Modified Extracellular Vesicles and Applications in Radiolabeling and Drug Delivery
by Elisa-Racky N’Diaye, Nicola Salvatore Orefice, Catherine Ghezzi and Ahcène Boumendjel
Pharmaceutics 2022, 14(3), 653; https://doi.org/10.3390/pharmaceutics14030653 - 16 Mar 2022
Cited by 10 | Viewed by 2683
Abstract
Extracellular vesicles (EVs) have been exploited as bio-inspired drug delivery systems (DDS) in the biomedical field. EVs have more advantages than synthetic nanoparticles: they are naturally equipped to cross extra- and intra-cellular barriers. Furthermore, they can deliver functional biomolecules from one cell to [...] Read more.
Extracellular vesicles (EVs) have been exploited as bio-inspired drug delivery systems (DDS) in the biomedical field. EVs have more advantages than synthetic nanoparticles: they are naturally equipped to cross extra- and intra-cellular barriers. Furthermore, they can deliver functional biomolecules from one cell to another even far away in the body. These advantages, along with obtained promising in vivo results, clearly evidenced the potential of EVs in drug delivery. Nevertheless, due to the difficulties of finding a chemical approach that is coherent with EVs’ rational clinical therapeutic use, those in the drug delivery community are expecting more from EVs’ use. Therefore, this review gathered knowledge of the current chemical approaches dealing with the conjugation of EVs for drugs and radiotracers. Full article
Show Figures

Graphical abstract

Back to TopTop